Clinical Trials
5 trialsNCT02426125 2023-08-21
RANGE
Eli Lilly and Company
Phase 3 Completed
NCT00004223 2023-06-18
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02437370 2022-10-18
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
University of California, Davis
Phase 1 Completed
NCT01282463 2019-09-09
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed